Clinical trials: Apixaban
Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the…
- Conditions
- Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus, Prophylaxis
- Trial name
- POTAMI (NCT06742567)
- Testing
- Apixaban 2.5 MG PO BID, Control (Standard treatment)
- Where
- Pakistan
- Volunteers
- 472 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Venous Thromboembolism
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
This study is to evaluate the effects of multiple-dose clarithromycin on the single-dose pharmacokinetics (PK) of apixaban with parameters like Cmax, AUC(INF), and AUC(0-T).
- Trial name
- NCT02912234
- Testing
- Apixaban, Clarithromycin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Embolism Thrombosis
Assessment of The Effect of Apixaban in AF
This study will assess the effect of apixaban on thrombotic status in patients with atrial fibrillation.In addition it will compare apixaban to aspirin and warfarin on their effect on endogenous fibrinolysis.
- Trial name
- NCT03199521
- Testing
- Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- East and North Hertfordshire NHS Trust
Transcatheter Aortic Valve Replacement
Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)
The main objective of this study is to demonstrate that a single anticoagulant therapy is superior to a combination of anticoagulant and antiplatelet therapy on the net clinical benefit estimated at 12 months after a…
- Trial name
- AVATAR (NCT02735902)
- Testing
- Vitamin K antagonist or direct oral anticoagulant treatment, Aspirin
- Where
- 6 sites in France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Healthy
Food Effect Study For Apixaban Commercial Image Tablets
To evaluate the effect of food on the pharmacokinetics of apixaban administered as commercial image tablets.
- Trial name
- NCT01437839
- Testing
- Apixaban
- Where
- Singapore
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Left Ventricular Thrombus
Apixaban in Patients With Left Ventricular Thrombus
Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).
- Trial name
- NCT05208398
- Testing
- Apixaban, Warfarin
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- Saud Al Babtain Cardiac Center
Atrial Fibrillation
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
Apixaban is a direct anticoagulant, which inhibits the factor Xa. Its clinical efficiency in prevention of stroke and systemic embolism in adult patients with NVAF (non/valvular atrial fibrillation) was demonstrated as well as…
- Trial name
- SPAF (NCT03441633)
- Testing
- apixaban, dabigatran, VKA
- Where
- Spain
- Volunteers
- 51,690 people
- Sponsor
- Pfizer
Pulmonary Embolism, Venous Thromboembolism
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a…
- Trial name
- STRATEGY-PE (NCT07603700)
- Testing
- Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
End-stage Renal Disease
Apixaban in Hemodialysis
This study aims to determine the effects of end-stage renal disease on the pharmacokinetics, pharmacodynamics, safety, and tolerability of apixaban. This is a single-center open-label pharmacological study.
- Trial name
- NCT02672709
- Testing
- apixaban
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Jewish General Hospital
Atrial Fibrillation, Cardioversion
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between…
- Conditions
- Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke
- Trial name
- AFTER-CV (NCT01924065)
- Testing
- Cardioversion, Oral Anticoagulant
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Suleyman Demirel University
Atrial Fibrillation
A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)
The purpose of this observational study is to identify participants with both minor and major bleeds as a result of anticoagulant treatment for AF and evaluating their QoL through both primary and secondary care settings.
- Trial name
- EQUAL-AF (NCT05044533)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI)
Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial…
- Conditions
- Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, AF - Atrial Fibrillation
- Trial name
- HERO-AF-AMI (NCT07583784)
- Testing
- DAT (DOAC+clopidogrel), DOAC monotherapy
- Where
- South Korea
- Volunteers
- 860 people
- Sponsor
- Chonnam National University Hospital
Wound Bleeding
Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B
The goal of this clinical trial is to test if the study drug, BXP154B works to stop bleeding from a minor wound in patients that are on apixaban for anticoagulant therapy.
- Trial name
- NCT06205615
- Testing
- BXP154B, Punch Biopsy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Bio 54, LLC
Neoplasms, Embolism
Anticoagulation in Patients With Venous Thromboembolism and Cancer
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect…
- Trial name
- VICTORIE (NCT04618913)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Atrial Fibrillation
Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation
Atrial fibrillation (AF) is the most common cardiac arrhythmias with a constantly growing prevalence AF. The purpose of paroxysmal AF processing is to control outbreaks from these pulmonary veins, medicated way (antiarrhythmic)…
- Trial name
- NACO-VP (NCT02814955)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Caen
Atrial Fibrillation
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).
- Trial name
- NCT02792335
- Testing
- apixaban, dabigatran, rivaroxaban
- Volunteers
- 28,000 people
- Sponsor
- Bristol-Myers Squibb
Aortic Valve Disease
DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
DIAMOND study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with aortic bioprosthesis (excluding TAVI) at least 7 days after cardiac surgery.
- Trial name
- DIAMOND (NCT05687448)
- Testing
- Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-valvular Atrial Fibrillation
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
- Trial name
- AEGEAN (NCT01884350)
- Testing
- Apixaban
- Where
- 220 sites in Belgium, France and 5 more
- Volunteers
- 1,217 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke, Transient Ischemic Attack
Eliquis Acute Stroke Safety Evaluation
Study Design: This is an investigator-initiated prospective, open label, single arm phase IV study. Patients with documented non-valvular atrial fibrillation (AF) with acute TIA (defined as acute focal neurological deficits, with…
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Atrial Fibrillation
- Trial name
- EASSE (NCT04435418)
- Testing
- Apixaban
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Alberta
Antithrombic Drug
Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects
To compare the bioavailability and characterize the pharmacokinetic profile of the sponsor's test product relative to that of reference product after single oral dose administration in normal, healthy, adult, human subjects under…
- Trial name
- NCT06043297
- Testing
- Apixaban 5MG, Eliquis 5 mg
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi